

Gary R Matzke

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/11359400/gary-r-matzke-publications-by-year.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

74
papers

2,407
citations

26
h-index

48
g-index

79
ext. papers

2,665
ext. citations

3.9
avg, IF

4.32
L-index

| # | Paper | IF | Citations |
|----|--|-----|-----------|
| 74 | Impact of a pharmacist-physician collaborative care model on patient outcomes and health services utilization. <i>American Journal of Health-System Pharmacy</i> , 2018 , 75, 1039-1047 | 2.2 | 40 |
| 73 | Population health and medicine: Policy and financial drivers. <i>American Journal of Health-System Pharmacy</i> , 2017 , 74, 1413-1421 | 2.2 | 3 |
| 72 | The ADAPT online education program: A tool for practicing pharmacists delivering patient-centered care. <i>Journal of the American Pharmacists Association: JAPhA</i> , 2017 , 57, 601-607 | 1.7 | 6 |
| 71 | Influence of kidney disease on drug disposition: An assessment of industry studies submitted to the FDA for new chemical entities 1999-2010. <i>Journal of Clinical Pharmacology</i> , 2016 , 56, 390-8 | 2.9 | 11 |
| 70 | Improving Health of At-Risk Rural Patients project: A collaborative care model. <i>American Journal of Health-System Pharmacy</i> , 2016 , 73, 1760-1768 | 2.2 | 6 |
| 69 | Medication adherence challenges among patients experiencing homelessness in a behavioral health clinic. <i>Research in Social and Administrative Pharmacy</i> , 2015 , 11, e110-20 | 2.9 | 37 |
| 68 | A Novel Education and Training Program to Enhance Student Advocacy. <i>American Journal of Pharmaceutical Education</i> , 2015 , 79, 95 | 2.5 | 4 |
| 67 | Principles of Drug Therapy in Patients with Reduced Kidney Function 2014 , 337-345 | | |
| 66 | Doripenem dosing recommendations for critically ill patients receiving continuous renal replacement therapy. <i>ISRN Pharmacology</i> , 2012 , 2012, 782656 | | 3 |
| 65 | Health care reform 2011: opportunities for pharmacists. <i>Annals of Pharmacotherapy</i> , 2012 , 46, S27-32 | 2.9 | 4 |
| 64 | Executive summary: The Virginia Commonwealth University pharmacy practice transformation conference. <i>Annals of Pharmacotherapy</i> , 2012 , 46, S1-11 | 2.9 | |
| 63 | The relationship between medication-related problems and behavioural health condition among patients served by a health care for the homeless centre. <i>Journal of Pharmaceutical Health Services Research</i> , 2012 , 3, 173-178 | 1 | 2 |
| 62 | Integration of collaborative medication therapy management in a safety net patient-centered medical home. <i>Journal of the American Pharmacists Association: JAPhA</i> , 2011 , 51, 167-72 | 1.7 | 33 |
| 61 | Influence of continuous venovenous hemofiltration and continuous venovenous hemodiafiltration on the disposition of doripenem. <i>Antimicrobial Agents and Chemotherapy</i> , 2011 , 55, 1187-93 | 5.9 | 16 |
| 60 | Health Care Policy 2011: implications for pharmacists. <i>Annals of Pharmacotherapy</i> , 2011 , 45, 412-3 | 2.9 | 3 |
| 59 | Development and Implementation of an Academic-Community Partnership to Enhance Care among Homeless Persons. <i>Innovations in Pharmacy</i> , 2011 , 2, 1-7 | 0.6 | 5 |
| 58 | Health-care reform 2010: how will it impact you and your practice?. <i>Annals of Pharmacotherapy</i> , 2010 , 44, 1485-91 | 2.9 | 7 |

| | | | |
|----|--|-----|-----|
| 57 | Evaluation of renal drug dosing: prescribing information and clinical pharmacist approaches. <i>Pharmacotherapy</i> , 2010 , 30, 776-86 | 5.8 | 52 |
| 56 | Antimicrobial dosing concepts and recommendations for critically ill adult patients receiving continuous renal replacement therapy or intermittent hemodialysis. <i>Pharmacotherapy</i> , 2009 , 29, 562-77 | 5.8 | 123 |
| 55 | Principles of Drug Therapy in Patients with Reduced Kidney Function 2009 , 322-329 | | |
| 54 | An in vivo-in vitro study of cefepime and ceftazidime dialytic clearance during high-flux hemodialysis. <i>Pharmacotherapy</i> , 2008 , 28, 977-83 | 5.8 | 13 |
| 53 | Antibiotics: Antianaerobic Agents, Quinolones, and Tetracyclines. <i>Seminars in Dialysis</i> , 2007 , 1, 220-223 | 2.5 | |
| 52 | Antifungal, Antitubercular, and Antiviral Agents. <i>Seminars in Dialysis</i> , 2007 , 1, 170-173 | 2.5 | 2 |
| 51 | Antibiotics: Vancomycin. <i>Seminars in Dialysis</i> , 2007 , 2, 54-55 | 2.5 | |
| 50 | Doses of histamine-2-receptor antagonists should be reduced in patients with low glomerular filtration rate. <i>Nature Clinical Practice Nephrology</i> , 2006 , 2, 298-9 | | 1 |
| 49 | Life on Capitol Hill: A pharmacist's perspective. <i>American Journal of Health-System Pharmacy</i> , 2006 , 63, 725-30 | 2.2 | 0 |
| 48 | Effect of conjugated equine estrogens on oxidative metabolism in middle-aged and elderly postmenopausal women. <i>Journal of Clinical Pharmacology</i> , 2006 , 46, 1299-307 | 2.9 | 13 |
| 47 | Liver disease selectively modulates cytochrome P450-mediated metabolism. <i>Clinical Pharmacology and Therapeutics</i> , 2006 , 80, 235-45 | 6.1 | 171 |
| 46 | Hepatic drug metabolism and transport in patients with kidney disease. <i>American Journal of Kidney Diseases</i> , 2003 , 42, 906-25 | 7.4 | 89 |
| 45 | Impaired 6-hydroxychlorzoxazone elimination in patients with kidney disease: Implication for cytochrome P450 2E1 pharmacogenetic studies. <i>Clinical Pharmacology and Therapeutics</i> , 2003 , 74, 555-68 | 6.1 | 6 |
| 44 | Status of Hemodialysis of Drugs in 2002. <i>Journal of Pharmacy Practice</i> , 2002 , 15, 405-418 | 1.3 | 12 |
| 43 | Characterization of tubular functional capacity in humans using para-aminohippurate and famotidine. <i>Kidney International</i> , 2001 , 59, 295-303 | 9.9 | 15 |
| 42 | Evaluation of the influence of diabetes mellitus on antipyrine metabolism and CYP1A2 and CYP2D6 activity. <i>Pharmacotherapy</i> , 2000 , 20, 182-90 | 5.8 | 53 |
| 41 | Determinants of ceftriaxone clearance by continuous venovenous hemofiltration and hemodialysis. <i>Pharmacotherapy</i> , 2000 , 20, 635-43 | 5.8 | 34 |
| 40 | Determinants of ceftazidime clearance by continuous venovenous hemofiltration and continuous venovenous hemodialysis. <i>Antimicrobial Agents and Chemotherapy</i> , 2000 , 44, 1639-44 | 5.9 | 35 |

| | | | |
|----|--|-----|-----|
| 39 | Nephrology pharmaceutical care preceptorship: a programmatic and clinical outcomes assessment. <i>Annals of Pharmacotherapy</i> , 2000 , 34, 593-9 | 2.9 | 6 |
| 38 | Comparison of iothalamate clearance methods for measuring GFR. <i>Pharmacotherapy</i> , 1999 , 19, 943-50 | 5.8 | 14 |
| 37 | A primer on continuous renal replacement therapy for critically ill patients. <i>Annals of Pharmacotherapy</i> , 1998 , 32, 362-75 | 2.9 | 81 |
| 36 | Use of chlorzoxazone as an in vivo probe of cytochrome P450 2E1: choice of dose and phenotypic trait measure. <i>Journal of Clinical Pharmacology</i> , 1998 , 38, 82-9 | 2.9 | 27 |
| 35 | Drug administration in patients with renal insufficiency. Minimising renal and extrarenal toxicity. <i>Drug Safety</i> , 1997 , 16, 205-31 | 5.1 | 68 |
| 34 | Validation of the five-drug "Pittsburgh cocktail" approach for assessment of selective regulation of drug-metabolizing enzymes. <i>Clinical Pharmacology and Therapeutics</i> , 1997 , 62, 365-76 | 6.1 | 206 |
| 33 | Effects of liver disease on the disposition of the opioid antagonist nalmefene. <i>Clinical Pharmacology and Therapeutics</i> , 1997 , 61, 15-23 | 6.1 | 17 |
| 32 | Analgesics and the kidney: summary and recommendations to the Scientific Advisory Board of the National Kidney Foundation from an Ad Hoc Committee of the National Kidney Foundation. <i>American Journal of Kidney Diseases</i> , 1996 , 27, 162-5 | 7.4 | 155 |
| 31 | Nonrenal toxicities of acetaminophen, aspirin, and nonsteroidal anti-inflammatory agents. <i>American Journal of Kidney Diseases</i> , 1996 , 28, S63-70 | 7.4 | 25 |
| 30 | The effect of renal insufficiency and hemodialysis on the pharmacokinetics of nalmefene. <i>Journal of Clinical Pharmacology</i> , 1996 , 36, 144-51 | 2.9 | 13 |
| 29 | Pharmacokinetics of abecarnil in patients with renal insufficiency. <i>Clinical Pharmacology and Therapeutics</i> , 1996 , 59, 520-8 | 6.1 | 5 |
| 28 | Effect of renal insufficiency on CYP activity.. <i>Clinical Pharmacology and Therapeutics</i> , 1996 , 59, 155-155 | 6.1 | 6 |
| 27 | Medication knowledge and compliance among patients receiving long-term dialysis. <i>American Journal of Health-System Pharmacy</i> , 1995 , 52, 1895-900 | 2.2 | 36 |
| 26 | Effects of hemodialysis on plasma protein binding of bepridil. <i>Journal of Clinical Pharmacology</i> , 1995 , 35, 137-41 | 2.9 | 3 |
| 25 | The pharmacodynamics of intravenous and oral torsemide in patients with chronic renal insufficiency. <i>Clinical Pharmacology and Therapeutics</i> , 1994 , 56, 39-47 | 6.1 | 41 |
| 24 | Pharmacotherapeutic consequences of recent advances in hemodialysis therapy. <i>Annals of Pharmacotherapy</i> , 1994 , 28, 512-4 | 2.9 | 9 |
| 23 | The pharmacokinetics of intravenous and oral torsemide in patients with chronic renal insufficiency. <i>Clinical Pharmacology and Therapeutics</i> , 1994 , 56, 31-8 | 6.1 | 26 |
| 22 | Clinical Pharmacokinetics of Anti-Infectives 1992 , 627-642 | | 4 |

| | | | |
|----|---|-----|-----|
| 21 | Antimicrobial Treatment of Peritonitis Associated with Continuous Ambulatory Peritoneal Dialysis. <i>Peritoneal Dialysis International</i> , 1991 , 11, 252-260 | 2.8 | 47 |
| 20 | Pharmacokinetics of cefepime in subjects with renal insufficiency. <i>Clinical Pharmacology and Therapeutics</i> , 1990 , 48, 268-76 | 6.1 | 103 |
| 19 | Validity of creatinine clearance estimates in the assessment of renal function. <i>Clinical Pharmacology and Therapeutics</i> , 1990 , 48, 503-8 | 6.1 | 104 |
| 18 | Disposition of antipyrine and acetaminophen given alone and in combination to human subjects. <i>Pharmaceutical Research</i> , 1990 , 7, 204-7 | 4.5 | 7 |
| 17 | Clinical pharmacokinetics 1990. <i>Clinical Pharmacokinetics</i> , 1990 , 18, 1-19 | 6.2 | 8 |
| 16 | Disposition of minoxidil in patients with various degrees of renal function. <i>Journal of Clinical Pharmacology</i> , 1989 , 29, 798-802 | 2.9 | 16 |
| 15 | Disposition of guanadrel in subjects with normal and impaired renal function. <i>Journal of Clinical Pharmacology</i> , 1989 , 29, 128-32 | 2.9 | 7 |
| 14 | Pharmacokinetics and pharmacodynamics of codeine in end-stage renal disease. <i>Clinical Pharmacology and Therapeutics</i> , 1988 , 43, 63-71 | 6.1 | 72 |
| 13 | Suprofen-induced uricosuria. A potential mechanism for acute nephropathy and flank pain. <i>American Journal of Nephrology</i> , 1988 , 8, 90-5 | 4.6 | 14 |
| 12 | Gentamicin disposition in young and elderly patients with various degrees of renal function. <i>Journal of Clinical Pharmacology</i> , 1987 , 27, 216-20 | 2.9 | 24 |
| 11 | Protein binding of phenytoin, p-hydroxy phenytoin, and p-hydroxy phenytoin glucuronide. <i>Journal of Clinical Pharmacology</i> , 1986 , 26, 677-9 | 2.9 | 5 |
| 10 | Disposition of vancomycin during hemofiltration. <i>Clinical Pharmacology and Therapeutics</i> , 1986 , 40, 425-30 | 6.1 | 45 |
| 9 | Cefotaxime and desacetyl cefotaxime kinetics in renal impairment. <i>Clinical Pharmacology and Therapeutics</i> , 1985 , 38, 31-6 | 6.1 | 25 |
| 8 | Protein binding of disopyramide and elevated alpha-1-acid glycoprotein concentrations in serum obtained from dialysis patients and renal transplant recipients. <i>American Journal of Nephrology</i> , 1985 , 5, 35-9 | 4.6 | 39 |
| 7 | Heparin interferes with tobramycin serum concentration determinations by Emit. <i>Drug Intelligence & Clinical Pharmacy</i> , 1984 , 18, 517-9 | | 3 |
| 6 | Gentamicin and tobramycin dosing guidelines: an evaluation. <i>Drug Intelligence & Clinical Pharmacy</i> , 1983 , 17, 425-32 | | 13 |
| 5 | Controlled comparison of gentamicin and tobramycin nephrotoxicity. <i>American Journal of Nephrology</i> , 1983 , 3, 11-7 | 4.6 | 66 |
| 4 | Evaluation of three gentamicin serum assay techniques. <i>Therapeutic Drug Monitoring</i> , 1982 , 4, 195-200 | 3.2 | 6 |

- 3 Documenting the influence of clinical pharmacists. *American Journal of Health-System Pharmacy*, **1982**, 39, 481-482 2.2
- 2 Nephropathy as a hazard of analgesic abuse. *American Journal of Health-System Pharmacy*, **1981**, 38, 1536-1540
- 1 Effect of quinidine on serum digoxin concentrations. *American Journal of Health-System Pharmacy*, **1979**, 36, 968-971 2.2